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Hypertension is the most prevalent risk factor for stroke,
myocardial infarction, or end-stage renal failure. The critical
importance of excess salt intake in the pathogenesis of
hypertension is widely recognized, but the mechanisms
whereby salt intake elevates blood pressure have puzzled
researchers. Recent studies using Naþ /Ca2þ exchange
inhibitors and genetically engineered mice provide evidence
that vascular Naþ /Ca2þ exchanger type 1 (NCX1) is involved
in the development of salt-dependent hypertension.
Endogenous cardiac glycosides, which may contribute to
salt-dependent hypertension, seem to be necessary for
NCX1-mediated hypertension. Intriguingly, studies using
knock-in mice with modified cardiac glycoside binding
affinity of Naþ ,Kþ -ATPases provide a clear demonstration
that this cardiac glycoside-binding site plays an important
role in blood pressure regulation. Taken all together:
(1) endogenous cardiac glycosides are secreted after high salt
intake; (2) these cardiac glycosides inhibit Naþ ,Kþ -ATPase
in vascular smooth muscle cells; (3) this inhibition results in
the elevation of local Naþ on the submembrane area; and
(4) this elevation of local Naþ facilitates Ca2þ entry through
NCX1, resulting in vasoconstriction. This proposed pathway
may have enabled us to explain how to link dietary salt to
hypertension.
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Hypertension, commonly referred to as ‘high blood pressure
(BP)’, is the most prevalent risk factor for stroke, myocardial
infarction, or end-stage renal failure. Insufficiently treated
hypertension can result in the most common causes of
disability or death. Epidemiological studies and clinical
trials with antihypertensive drugs, as well as studies using
experimental hypertensive animal models, have provided
critical insights on the relationship between dietary salt
intake and high BP.1–3 Numerous basic and clinical studies
have suggested that the mechanism of salt-dependent
hypertension is related to the dysfunction of the kidneys, as
originally proposed by Guyton.4 However, the mechanisms
by which dietary salt intake elevates arterial BP are not
fully understood. Hypertension is a multifactorial disease,
in which genetic and environmental factors are intricately
involved. Indeed, all patients with essential hypertension
are not necessarily salt-sensitive, and are divided into two
groups: salt-sensitive and salt-insensitive patients.5
Thus far, several reports have shown a correlation between
elevated levels of endogenous cardiac glycosides (ECGs), such
as ouabain, marinobufagenin, proscillaridin A, and bufalin,
and salt-dependent hypertension,6–9 although the physiological
function of ECGs is still uncertain. Recently, we demonstrated
by using pharmacological tools and genetically engineered
mice that salt-dependent hypertension is triggered by Ca2þ
entry through Naþ /Ca2þ exchanger type-1 (NCX1) in arterial
smooth muscle cells.10 The implications of these findings
include the following: (1) Naþ /Ca2þ exchange inhibitors
lower arterial BP in salt-dependent hypertensive animals, but
not in other types of hypertensive animals; (2) heterozygous
mice with reduced expression of NCX1 are resistant to
developing salt-dependent hypertension, whereas transgenic
mice with vascular smooth muscle-specific overexpression of
NCX1 readily develop hypertension after high salt-loading; and
(3) Naþ /Ca2þ exchange inhibitors restore the vasoconstriction
induced by nanomolar ouabain. Quite recently, using knock-in
mice with modified ECG binding affinity of Naþ ,Kþ -ATPases,
Lingrel’s group demonstrated that this ECG-binding site plays
an important role in controlling BP, and gave support to the
hypothesis that the ECGs have a cardiovascular role.11,12
In this review, we discuss the molecular mechanism link-
ing dietary salt to hypertension, and propose that vascular
NCX1 as well as Naþ ,Kþ -ATPase is a new therapeutic or
diagnostic target for salt-dependent hypertension.
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A LINK BETWEEN DIETARY SALT INTAKE AND ARTERIAL BP
The effect of high salt intake on BP
Epidemiological, genetic, physiological, and biochemical
studies provide conclusive evidence of a critical link between
dietary salt intake and BP. Dahl’s findings on the relationship
between excess salt intake and the incidence of hyperten-
sion marked a milestone in our understanding of these
processes.13 The large-scale epidemiological study Interna-
tional Study of Salt and BP (INTERSALT) examined the
relationship between 24-h urinary salt excretion and BP
worldwide.14 In this study, initial calculations indicated
that urinary salt excretion is significantly associated with BP
in individuals. In cross-center analysis, the effect of higher
median salt excretion (5.7 g/day) over a 30-year period was
estimated to be a difference of 10 and 6 mm Hg in systolic
and diastolic BP, respectively. Another study, Cardiovascular
Diseases and Alimentary Comparison (CARDIAC) also
indicated positive correlations between urinary salt excretion
and systolic or diastolic BP in males from cross-center
analysis (0.98 and 0.68 mm Hg per urinary salt excretion
(g/day) for systolic and diastolic BP, respectively).15
In experimental animals, the available data verify our
current understanding of the relationship between dietary
salt intake and BP. When adult baboons were treated with
a high-salt diet (4% salt) and drinking water containing
1% salt for 1 year, the systolic and diastolic BP were elevated
by 33 and 10 mm Hg, respectively.16 In African green
monkeys, a diet containing 6% salt for 3 months significantly
increased the systolic and diastolic BP by 27 and 15 mm Hg,
respectively.17 A colony of chimpanzees given a high-salt
diet (5–10 g/day) for 70 weeks developed a highly significant
rise in systolic and diastolic BP (33 and 10 mm Hg, respec-
tively).18 In addition, it is well known that Dahl salt-sensitive
rats, a genetic animal model of hypertension, develop
hypertension when they are fed a high-salt diet.19 Sponta-
neously hypertensive rats are also susceptible to salt-induced
hypertension, although they exhibit hypertension and
end-organ damage without high salt treatment.20 Thus,
various findings indicate that dietary salt is positively
associated with BP.
The effects of high salt intake on plasma sodium and
extracellular fluid volume
In humans and experimental animals, excess salt intake
acutely increases plasma sodium and extracellular fluid
volume, subsequently leading to high BP.21–24 In normoten-
sive subjects, the acute change of salt intake from 50 to
300 mmol/day for 14 days caused a significant increase in
plasma sodium by 1.6 mmol/l with an elevation in systolic
and diastolic BP (17 and 6 mm Hg, respectively).21 In Dahl
salt-sensitive rats, a high salt intake for 4 days significantly
raised plasma sodium (3 mmol/day) with an increase in mean
BP (32 mm Hg).22 High BP induced by salt-loading, however,
does not result directly from an acute increase in extracellular
fluid volume, because rapid volume expansion (i.e., intra-
venous infusion of saline) does not raise BP.25 On the other
hand, others have proposed that volume expansion leads
to the rise in arterial BP via the autoregulated constriction
of resistance vessels, which accompanies an initial increase
in cardiac output.26 However, there are several reports show-
ing that cardiac output does not regulate BP.3 Taken together,
acute changes in plasma sodium and extracellular fluid
volume are potentially, but not strictly, sufficient for control-
ling BP. Prolonged increases in dietary salt intake or dysfunc-
tion of the kidney also cause a persistent increase in plasma
sodium, which is closely related to an elevation in BP.
RENAL MECHANISMS RELATED TO SALT-DEPENDENT
HYPERTENSION
The evidence for a relationship between renal dysfunction
and salt-dependent hypertension
The kidney seems to play a primary role in the functional
disturbances that link salt intake to BP.3,4 Indeed, renal
cross-transplantation studies between hereditary hyper-
tensive and normotensive rats show that the abnormal
kidney is ultimately responsible for the rise in BP.19,27 When
terminal nephrosclerosis patients with hypertension are
transplanted with a kidney from a normotensive donor,
the BP consistently drops to the normal range.28 Further-
more, the primacy of the kidney in controlling BP has been
confirmed by Guyton’s pressure natriuresis theory.4 Recently,
Johnson et al.21 suggested that subtle, acquired renal dysfunc-
tion (i.e., renal microvascular or tubulointerstitial injury)
becomes the most likely mechanism to link dietary salt
to hypertension. Thus, a defect in renal sodium handling
may be responsible for the development of salt-dependent
hypertension.
The evidence for genetic effects on renal salt handling
Numerous genetic analyses of severe hypertension or
hypotension in families identify several mutations in single
genes that cause Mendelian syndromes in humans.3,29
Importantly, these genes encode proteins which are involved
in the control of renal salt handling, such as ion channels and
transporters. Mutations enhancing renal salt reabsorption
raise BP, whereas those reducing salt reabsorption lower BP.
In particular, a-adducin and the epithelial sodium channel
(ENaC) seem to play a critical role in regulating urinary
excretion of salt, sodium balance, and BP.
a-Adducin is a cytoskeletal protein that modulates
Naþ ,Kþ -ATPase activity in the renal tubular cells.30 The
Gly460Trp variant of the a-adducin gene is related to higher
prevalence of hypertension in several populations.31,32
Hypertensive patients carrying this variant have enhanced
Naþ ,Kþ -ATPase activity, and subsequently exhibit an
increased rate of proximal tubule sodium reabsorption.33
Interestingly, in these patients, increased levels of ECGs
have been found to accompany the development of hyper-
tension.34 In Milan hypertensive rats – a genetic model
with two missense mutations of a-adducin (Phe316Tyr)
and b-adducin (Gln529Arg) – enhanced tubular sodium
reabsorption and increased ECG levels are also observed.35,36
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Liddle syndrome is associated with mutations in either the
b- or g-subunit of ENaC that truncate their cytoplasmic
C termini.37,38 Normally, these C terminal tails, containing
the sequence PPPXY motif, interact with Ndd4-2, an E3
ligase, resulting in ubiquitination and proteasome-mediated
degradation of ENaC.39 The deletion of this motif from
the b- or g-subunit of ENaC leads to prolongation of
the ;cell surface half-life of channels in the collecting duct,
and consequently an increase in sodium reabsorption. The
abnormalities in Liddle syndrome, such as salt-dependent
hypertension associated with hypokalemic alkalosis and
low plasma renin activity, can be improved by a low-salt
diet and amiloride, an ENaC inhibitor.
CARDIOVASCULAR MECHANISMS RELATED TO
SALT-DEPENDENT HYPERTENSION
The evidence for a relationship between high salt intake and
cardiovascular functions
Excess dietary salt increases stiffness of conduit arteries,
thickness and narrowness of resistance arteries, and the mass
of the left ventricular wall, as a result of high sodium as well
as of salt-induced high BP.40–42 There is some evidence that a
rise in plasma sodium directly causes functional or structural
changes in the blood vessels or heart which could contribute
to salt-dependent hypertension. Blaustein43 pointed out that
a rise of intracellular Naþ concentration ([Naþ ]i) in vascular
smooth muscle cells produces vasoconstriction because of the
resultant increase in intracellular Ca2þ concentration
([Ca2þ ]i). Friedman et al.
44 found that the plasma level of
sodium is directly related to the systolic and diastolic BP in
rats intraperitoneally dialyzed with physiological salt solu-
tions containing variable amounts of sodium. In normoten-
sive and hypertensive subjects, urinary sodium excretion, as
used to estimate salt intake, is significantly correlated with
the mass of the left ventricular wall.45,46 Furthermore, in
humans and experimental animals, high salt intake stiffens
conduit arteries and thickens resistance arteries independent
of BP.41,47 Thus, sodium intake appears to directly induce
arterial and cardiac remodeling, although hypertension,
induced by high salt, actually leads to shear stress and stretch
in cardiovascular organs.
The effect of high salt intake on plasma levels of ECGs
The presence of a circulating Naþ ,Kþ -ATPase inhibitor was
first demonstrated in animals over 20 years ago, and a signi-
ficant correlation between BP and the activity of Naþ ,Kþ -
ATPase inhibitor has been found.48 Since then, several ECGs,
such as endogenous ouabain6 and other steroids7–9 including
marinobufagenin, proscillaridin A, and bufalin, have been
identified thus far as candidate intermediaries in the
pathogenesis of essential hypertension (especially salt-sensi-
tive hypertension). Endogenous ouabain is synthesized and
secreted by the adrenal gland49,50 and hypothalamus.51 In
humans, prolonged increases in dietary salt intake cause
the levels of ECGs to rise in the plasma.48,52,53 Moreover,
among patients with essential hypertension, almost half have
substantially elevated levels of endogenous ouabain.54,55
Plasma levels of ECGs are also high in several salt-dependent
hypertensive animals.6,53,56 Thus, these ECGs may be
involved in the etiology of salt-dependent hypertension.
Furthermore, among patients with congestive heart failure,
about half show increased levels of endogenous ouabain, and
in these patients the ouabain level is inversely correlated with
the cardiac index.57 This suggests that the secretion of
ouabain is enhanced as a compensatory response in heart
failure patients. It is generally believed that ECGs inhibit the
plasma membrane (PM) Naþ ,Kþ -ATPase and lead to an
increase in [Naþ ]i. Cell Na
þ accumulation raises the level of
[Ca2þ ]i probably through the involvement of the Na
þ /Ca2þ
exchanger, and thereby increases contraction and Ca2þ -
dependent signaling in vascular smooth muscle or heart
muscle, as originally postulated by Blaustein and Hamlyn.58
The role of vascular Naþ /Ca2þ exchanger in salt-dependent
hypertension
The Naþ /Ca2þ exchanger is an ion transporter, which
transports Ca2þ either out of cells or into cells (i.e., the
forward mode and reverse mode, respectively) in exchange
for 3Naþ .59–61 This transporter is controlled by membrane
potential and transmembrane gradients of Naþ and Ca2þ .
There are three Naþ /Ca2þ exchanger isoforms (NCX1,
NCX2, and NCX3) in mammals.60 NCX1 is widely expressed
in the heart, kidney, brain, arteries, and other organs, whereas
NCX2 and NCX3 expression is limited mainly to the brain.62
Extensive alternative splicing of NCX1 generates at least
12 tissue-specific variants; the heart expresses exclusively
NCX1.1, and vascular tissue predominantly NCX1.3.62 These
exchangers are modulated by at least two inactivation
systems: I1 and I2 inactivations.
63 High intracellular Naþ
restrains Naþ /Ca2þ exchange by facilitating exchanger
entry into the I1 inactivation state.
64 On the other hand,
intracellular Ca2þ binding to regulatory Ca2þ sites in a
large cytoplasmic domain stimulates Naþ /Ca2þ exchange
by promoting exchanger recovery from the I2 inactivation
state.65
In vascular smooth muscle cells, the Naþ /Ca2þ exchan-
ger, like Ca2þ -ATPases, is thought to contribute to Ca2þ
extrusion from the cytosol in the relaxation process.59–61
Immunocytochemical staining of vascular smooth muscle
cells indicated that the Naþ /Ca2þ exchanger is localized in
the PM regions that are adjacent to junctional sarcoplasmic
reticulum (SR).66,67 This particular localization suggests that
the Naþ /Ca2þ exchanger may play a role in regulating the
Ca2þ content of the SR stores, thereby modulating Ca2þ
handling and vasocontraction. Recent data obtained using
antisense oligonucleotides indicate that NCX1 knockdown
prolongs agonist responses by delaying the return of [Ca2þ ]i
to the resting level, and also inhibits ouabain-induced
augmentation of agonist responses in [Ca2þ ]i in cultured
vascular smooth muscle cells.68,69 Furthermore, reduced
expression of NCX1 in aortas from NCX1 heterozygous
mice decelerated Naþ -dependent relaxation and contrac-
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tion.70 These findings suggest that the PM Naþ /Ca2þ
exchanger is involved in regulating Ca2þ homeostasis of
blood vessels.
Recently, we found that transgenic mice overexpressing
canine NCX1.3, the vascular isoform of NCX1, were
hypersensitive to salt, and the animals readily developed
hypertension after high salt intake.10 Oral administration of
SEA0400, a specific Naþ /Ca2þ exchange inhibitor, consis-
tently reduced the BP in salt-loaded NCX1.3-transgenic mice
as well as several salt-dependent hypertensive models.10
On the other hand, NCX1 heterozygous mice with reduced
expression (B50%) of NCX1 were resistant to salt-
dependent hypertension.10 These findings indicate that
vascular NCX1 plays an important role in the development
of salt-dependent hypertension.
The pathway from high salt intake to vasoconstriction
in salt-dependent hypertension
ECGs are thought to contribute to the pathogenesis of salt-
dependent hypertension, primary aldosteronism, and Cush-
ing’s syndrome in clinical patients and experimental animals
(Figure 1).52,53,71 Indeed, chronic administration of ouabain
to rats caused hypertension, which was suppressed by
SEA0400.10 We further found that the blood from deoxy-
corticosterone acetate-salt hypertensive rats contained
humoral vasoconstrictors. Importantly, arterial infusion of
SEA0400 counteracted the vasoconstriction induced by the
factor and exogenous ouabain in the femoral arteries of
experimental animals.10 These results indicate that excess
dietary salt increases ECGs and the latter may contract
peripheral blood vessels via vascular Naþ /Ca2þ exchanger
and thereby result in hypertension.
In vascular smooth muscle cells, inhibition of Naþ ,
Kþ -ATPase by ECGs should elevate local [Naþ ] just under
the PM (Figure 1). The restricted [Naþ ] accumulation
facilitates Ca2þ entry through the vascular NCX1; this
enhances arterial tone and causes hypertension. Notably, in
vascular smooth muscle cells, the NCX1 is colocalized with
the Naþ ,Kþ -ATPase a2-isoform, which has high affinity for
ouabain in rodents, in PM microdomains (‘plasmerosomes’)
adjacent to the SR.67,72 On the other hand, the distribution
of a1-isoform in the PM is relatively uniform.
72 The concept
of intracellular linked Ca2þ and Naþ transport at PM–SR
junctions in vascular smooth muscle cells is also known
as the ‘superficial buffer barrier’ function.73 Functional coup-
ling between Naþ /Ca2þ exchanger and Naþ ,Kþ -ATPase
has been reported in vascular smooth muscle cells and
cardiomyocytes.74,75
Dostanic-Larson et al.11 and Dostanic et al.12 demons-
trated that chronic administration of ouabain and adreno-
corticotropic hormone (ACTH), which is an animal model
related to the ACTH-dependent Cushing’s syndrome,
induced hypertension in wild-type mice, but not in knock-
in mice with a ouabain-resistant a2-isoform. These results
show that the highly conserved ECG-binding site of the
Naþ ,Kþ -ATPase a2-isoform plays an important role in
the regulation of BP, and also provide a clear demonstration
that an endogenous ligand for the Naþ ,Kþ -ATPase must
be present in animals (Figure 1). We found that nanomolar
ouabain increases both [Ca2þ ]i and myogenic tone in
pressurized mouse small mesenteric arteries, and that
ouabain antagonists (PST2238 and canrenone) and Naþ /
Ca2þ exchange inhibitors (SEA0400 and KB-R7943) abolish
these effects.10,76 The ouabain-induced [Ca2þ ]i rise in
arterial strips from NCX1.3-transgenic mice was greater than
in those obtained from wild-type mice.10 Furthermore,
SEA0400 blocked these [Ca2þ ]i rises in NCX1.3-transgenic
mice and wild-type mice. Interestingly, the isolated mesen-
teric arteries from heterozygous a2
þ / mice, but not those
from heterozygous a1
þ / mice, exhibited significantly greater
myogenic tone than those from the wild type.76 Taken
together, these findings provide evidence that ECGs trigger
Ca2þ entry through NCX1 in vascular smooth muscle cells
by inhibiting the Naþ ,Kþ -ATPase a2-isoform and elevating
submembrane Naþ (Figure 1).
In humans, the a1- and a2-isoforms have high affinity for
ouabain, but in rodents the a1-isoform has low ouabain
affinity. Quite recently, Dostanic-Larson et al.11 examined
whether the ECG-binding site of the Naþ ,Kþ -ATPase
a1-isoform can play a role in ACTH-induced hypertension.
Interestingly, knock-in mice with both ouabain-sensitive
a1-isoform and ouabain-resistant a2-isoform, but not mice
with both ouabain-resistant a1- and a2-isoforms, exhibited
ACTH-induced hypertension, suggesting that the a1-isoform
also plays a role in the regulation of BP. However, the basal
BP in a2
þ / mice, but not in a1

























Figure 1 | Proposed pathway responsible for salt-dependent
hypertension. High salt intake (or Naþ retention) and genetic or
pathological defects cause the levels of ECGs that inhibit the
Naþ ,Kþ -ATPase a2-isoform (or a1-isoform) to rise in the plasma
(although Naþ retention also increases plasma volume, resulting in
elevated blood pressure). This results in the increase in subplasma
membrane [Naþ ] of arterial smooth muscle. The restricted [Naþ ]
accumulation elevates [Ca2þ ]i by vascular NCX1 isoform (NCX1.3)-
mediated Ca2þ entry. This enhances arterial tone and causes
hypertension. SEA0400, as well as thiazides and PST2238, blocks this
Ca2þ entry and exerts an antihypertensive effect in salt-dependent
hypertension. SR; sarcoplasmic reticulum, RyR; ryanodine receptor.
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mice), was significantly higher than in wild-type mice.76
Therefore, further studies are necessary to determine the
physiological implications of the Naþ ,Kþ -ATPase a1-iso-
form in humans.
NEW APPROACHES FOR THE TREATMENT AND PREVENTION
OF SALT-DEPENDENT HYPERTENSION
Naþ /Ca2þ exchange inhibitors
Vascular Naþ /Ca2þ exchanger may play a key role in salt-
dependent hypertension, which makes the Naþ /Ca2þ
exchanger protein a fascinating drug target. Thus far, specific
Naþ /Ca2þ exchange inhibitors, such as KB-R7943,77 SN-6,78
SEA0400,79,80 and YM-244769,81 have been developed.61
These Naþ /Ca2þ exchange inhibitors, possessing a common
benzyloxyphenyl structure, seem to interact with a specific
receptor site in the NCX1 molecule.78,80,82 Intriguingly,
benzyloxyphenyl inhibitors block the reverse mode (i.e.,
Ca2þ influx mode) of NCX1 much more effectively than
the forward mode (i.e., Ca2þ efflux mode).78,80,83 Recent
mutational and electrophysiological analyses provide an
explanation for the reverse mode-selectivity of benzyloxy-
phenyl derivatives.78,83 The inhibitory potency of Naþ /Ca2þ
exchange inhibitors is directly coupled to the rate of I1
inactivation (i.e., intracellular Naþ -dependent inactivation).
Under physiological conditions, the reverse mode is induced
when [Naþ ]i is high, whereas the forward mode is generated
when [Naþ ]i is reduced. NCX1 molecules thus tend to
undergo I1 inactivation in conditions for the reverse mode,
suggesting an apparent, but not substantial, reverse mode-
selectivity. These inhibitors likely stabilize the I1 inactivation
state or accelerate the rate of I1 inactivation. This proposed
mechanism suggests that benzyloxyphenyl inhibitors may be
relatively dormant under normal conditions (low [Naþ ]i),
but become effective under pathological conditions (high
[Naþ ]i). This should be an ideal profile for therapeutic
agents against intracellular Naþ -dependent cardiovascular
diseases, such as salt-dependent hypertension as well as
myocardial ischemia/reperfusion injury.
Indeed, the administration of SEA0400 dose-dependently
lowered arterial BP in salt-dependent hypertensive rat
models, such as deoxycorticosterone acetate-salt hypertensive
rats, salt-loaded Dahl salt-sensitive rats, and salt-loaded
spontaneously hypertensive rats, but not in normotensive
rats or other salt-independent types of hypertensive rats.10
This antihypertensive profile is unique, and differs from that
of Ca2þ channel blockers, which lower BP in almost all
hypertensive models. In addition, KB-R7943 abolished the
ACTH-induced hypertension, a model of Cushing’s syn-
drome, in mice.11 Thus, benzyloxyphenyl inhibitors selec-
tively suppress salt-dependent hypertension (that is, ECG-
dependent hypertension). Furthermore, long-term treatment
with SEA0400 overcomes the development of salt-dependent
hypertension, vascular hypertrophy, and renal dysfunction
in animal models.10 Very importantly, SEA0400 lowered the
BP in salt-loaded, NCX1.3-transgenic mice, but not in trans-
genic mice expressing an NCX1.3 mutant (Gly833Cys),
which lacked the affinity to SEA0400,10 showing that
SEA0400 specifically acts on the overexpressed NCX1.3 in
vascular smooth muscle cells. On the other hand, SEA0400
has little effect on BP (arterial tone) in normal animals,
probably owing to the low level of ECGs in the plasma.
Interestingly, SEA0400 inhibits the vascular isoform
(NCX1.3) more potently than the cardiac and neuronal
isoforms,10,80 indicating the vascular selectivity of SEA0400.
Thus, Naþ /Ca2þ exchange inhibitors like SEA0400 may have
new therapeutic or diagnostic potential for salt-dependent
hypertension (Figure 1).
Ouabain antagonists
Increased levels of endogenous ouabain, a major candidate
ECG, have been implicated in the development of salt-
dependent hypertension and related cardiovascular
diseases.9,51–54 The pathogenic mechanisms of endogenous
ouabain involve the inhibition of Naþ ,Kþ -ATPases in the
vascular vessels and kidneys, which are associated with
vasoconstriction and renal tubular reabsorption, respectively.
Therefore, ouabain antagonists have been targeted as a new
class of antihypertensive drugs (Figure 1). PST2238 (Rosta-
furoxin), a digitoxigenin derivative, is able to antagonize
ouabain-specific binding in Naþ ,Kþ -ATPases.84 PST2238
lowered BP in ouabain-dependent hypertensive models,85
subnephrectomized rats drinking saline solution,86 and Milan
hypertensive rats (an adducin mutant model),87 but not
in normotensive rats.85,87 This drug has no effect on general
or hormonal receptors involved in BP regulation.84,85 In
addition to inhibition of the Naþ ,Kþ -ATPase, ouabain
activates a signal transducing function, triggering cell growth
and proliferation.88 Very interestingly, PST2238 is able to
block ouabain-induced organ hypertrophy.89 Thus, PST2238
could be useful for the treatment of essential hypertension,
mainly related to Naþ handling alterations, and cardiac
complications which are associated with either increased
levels of endogenous ouabain or adducin polymorphism.84
CONCLUSION
Recent studies using genetically engineered mice and specific
inhibitors or modulators have provided compelling evidence
for the molecular mechanism linking salt to hypertension.
The links between dietary salt intake, ECGs, Naþ ,Kþ -
ATPase, and vascular NCX1 may lead to the elevation
of [Ca2þ ]i and contractility in arterial smooth muscle
cells, thereby resulting in hypertension (see Figure 1).
Notably, recent human genome-wide linkage analysis of
genes that affect BP identified four chromosomal regions,
one of which includes NCX1, as loci containing candidate
genes that influence BP.90 Furthermore, genetic analyses of
severe hypertension in families identified adducin poly-
morphism, associated with the Naþ ,Kþ -ATPase activity.31,32
Thiazide diuretics are widely used as antihypertensive
drugs. So far, thiazides have been thought to lower BP acutely
through diuretic action. However, the major antihypertensive
mechanism of thiazides during long-term administration
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seems to be due to vasodilation rather than to loss of plasma
volume by natriuresis.91,92 Therefore, there is a possibility
that thiazides indirectly inhibit vascular NCX1 by normal-
izing sodium balance and, subsequently, decreasing ECGs
(see Figure 1), resulting in suppressing salt-dependent
hypertension.
Naþ /Ca2þ exchange inhibitors and ouabain antagonists
might open new possibilities for the potential treatment
of hypertension and related cardiovascular diseases. PST2238
is currently in Phase II trials, whereas Naþ /Ca2þ exchange
inhibitors are undergoing preclinical development. Recent
clinical studies in Europe show that PST2238 effectively
lowers BP in essential hypertensive patients.84 Intriguingly,
both PST2238 and SEA0400 lack diuretic activity,10,84
subsequently resulting in no diuretic-associated side effects.
These drugs, if they are developed clinically, might lower BP
without the need for a tightly controlled low-salt diet.
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